Lisata Therapeutics, Inc. · DUS:8NE

Lisata Therapeutics, Inc. financial statements

Lisata Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue170.0K1.00M00000035.3M
Cost of revenue146.0K174.0K189.0K69.0K55.0K63.0K65.0K225.0K372.0K31.1M
Gross profit24.0K1.00M-189.0K63.8M-55.0K-63.0K-65.0K-225.0K-372.0K4.15M
Research and development7.95M11.3M12.7M13.1M17.7M9.25M10.8M7.59M15.8M16.7M
Selling, general and administrative10.4M12.1M13.0M14.1M11.5M9.89M9.29M9.39M11.8M12.8M
Operating income-18.2M-22.4M-25.7M-57.6M-29.1M-19.1M-20.1M-17.0M-27.6M-29.5M
Depreciation and amortization146.0K174.0K189.0K69.0K55.0K100.0K100.0K200.0K400.0K500.0K
EBITDA-18.1M-22.2M-25.5M-57.5M-29.0M-19.0M-20.0M-16.8M-27.2M-29.0M
Interest expense1.95M227.0K123.0K05.00K378.0K1.78M
Income before tax-17.5M-20.8M-23.2M-56.7M-29.0M-19.0M-19.4M-16.2M-27.7M-31.3M
Income tax-962.0K-798.0K-2.33M-2.48M-1.51M-10.9M00-11.5M0
Net income-16.6M-20.0M-20.8M-54.2M-27.5M-8.15M-19.4M-16.2M23.0M-32.7M
Earnings per share, basic-1.91-2.40-2.58-10.47-7.45-0.53-1.88-1.672.56-4.99
Earnings per share, diluted-1.91-2.40-2.58-10.47-7.45-0.53-1.88-1.672.56-4.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.0M16.2M22.6M32.2M24.6M16.5M14.0M10.3M29.2M7.08M
Short-term investments015.0M27.9M37.1M70.3M18.1M11.1M32.8M25.9M
Receivables0900.0K0234.5K138.8K
Inventory5.00M3.58M
Current assets17.7M34.6M53.9M71.9M96.2M35.3M26.0M44.1M61.4M24.6M
Property, plant and equipment18.0K72.0K175.0K296.0K62.0K57.0K100.0K165.0K257.0K705.4K
Goodwill07.01M
Total assets17.7M35.0M54.7M73.0M97.0M36.0M27.2M44.6M63.4M53.5M
Accounts payable1.02M1.28M2.42M2.65M1.93M1.02M1.49M762.0K1.34M2.23M
Current liabilities3.07M5.61M6.59M6.38M4.52M3.51M5.98M5.62M9.31M21.2M
Long-term debt02.52M
Total debt137.0K168.0K485.0K714.0K624.0K978.0K05.65M
Total liabilities3.14M5.68M6.80M6.71M5.01M3.76M6.60M7.13M13.2M30.0M
Shareholders' equity14.9M29.6M48.1M66.6M92.3M32.5M20.8M37.7M50.5M4.88M
Shares outstanding8.83M8.41M8.15M7.87M3.99M19.4M10.5M9.87M9.48M8.21M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-15.9M-19.4M-20.0M-21.2M-22.2M-8.82M-18.9M-20.0M-20.9M-23.7M
Capital spending-28.0K00-285.0K-60.0K-20.0K0-134.0K-135.0K-1.10M
Free cash flow-16.0M-19.4M-20.0M-21.5M-22.3M-8.84M-18.9M-20.1M-21.0M-24.8M
Cash from investing15.1M13.2M10.1M28.9M-54.9M-7.28M21.4M-4.71M41.3M-2.85M
Cash from financing599.0K-206.0K385.0K-224.0K85.3M18.6M1.18M824.0K-932.0K20.9M
Dividends paid-15.0M
Share buybacks-91-267-248-148-130-403-358-72
Change in cash-253.0K-6.38M-9.56M7.51M8.13M2.48M3.73M-23.9M19.5M-5.61M